Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

“We are excited to be participating in the SITC 2021 pre-conference workshop, and look forward to Dr. Reardon’s presentation: “INO-5401 and INO-9012 Delivered Intramuscularly (IM) with Electroporation (EP) in Combination with Cemiplimab (REGN2810) in Newly Diagnosed Glioblastoma."

Ino is analyzing data for OS30. Dr. Jeffrey Skolnik said “we still have yet to have reached median overall survival in our MGMT - methylated patients. That's a good thing that we haven't met that median yet. Pending those data, we'll really make decisions as to where we can bring this opportunity forward but in general, we're very encouraged by what certainly the key opinion leaders and the scientists and clinicians are telling us in this space.”

Patients can apply for Compassionate Use with FDA anytime now. There is a good market for it worldwide.

We are excited to be participating in the SITC 2021 pre-conference workshop, and look forward to Dr. Reardon’s presentation: “INO-5401 and INO-9012 Delivered Intramuscularly (IM) with Electroporation (EP) in Combination with Cemiplimab (REGN2810) in Newly Diagnosed Glioblastoma."

— INOVIO Pharmaceuticals (@InovioPharma) November 10, 2021